Literature DB >> 27375072

Does DCD Donor Time-to-Death Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States.

J R Scalea1, R R Redfield1, E Arpali1, G E Leverson1, R J Bennett2, M E Anderson2, D B Kaufman1, L A Fernandez1, A M D'Alessandro1, D P Foley1, J D Mezrich1.   

Abstract

For donation after circulatory death (DCD), many centers allow 1 h after treatment withdrawal to donor death for kidneys. Our center has consistently allowed 2 h. We hypothesized that waiting longer would be associated with worse outcome. A single-center, retrospective analysis of DCD kidneys transplanted between 2008 and 2013 as well as a nationwide survey of organ procurement organization DCD practices were conducted. We identified 296 DCD kidneys, of which 247 (83.4%) were transplanted and 49 (16.6%) were discarded. Of the 247 recipients, 225 (group 1; 91.1%) received kidneys with a time to death (TTD) of 0-1 h; 22 (group 2; 8.9%) received grafts with a TTD of 1-2 h. Five-year patient survival was 88.8% for group 1, and 83.9% for group 2 (p = 0.667); Graft survival was also similar, with 5-year survival of 74.1% for group 1, and 83.9% for group 2 (p = 0.507). The delayed graft function rate was the same in both groups (50.2% vs. 50.0%, p = 0.984). TTD was not predictive of graft failure. Nationally, the average maximum wait-time for DCD kidneys was 77.2 min. By waiting 2 h for DCD kidneys, we performed 9.8% more transplants without worse outcomes. Nationally, this practice would allow for hundreds of additional kidney transplants, annually. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; donors and donation: deceased; donors and donation: donation after circulatory death (DCD); health services and outcomes research; kidney transplantation/nephrology; organ allocation; organ procurement; organ procurement and allocation; organ procurement organization

Mesh:

Year:  2016        PMID: 27375072     DOI: 10.1111/ajt.13948

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

Review 1.  A few realistic questions raised by organ retrieval in the intensive care unit.

Authors:  Olivier Lesieur; Liliane Genteuil; Maxime Leloup
Journal:  Ann Transl Med       Date:  2017-12

2.  Use and Outcomes of Kidneys from Donation after Circulatory Death Donors in the United States.

Authors:  John Gill; Caren Rose; Julie Lesage; Yayuk Joffres; Jagbir Gill; Kevin O'Connor
Journal:  J Am Soc Nephrol       Date:  2017-10-05       Impact factor: 10.121

3.  A kidney offer acceptance decision tool to inform the decision to accept an offer or wait for a better kidney.

Authors:  Andrew Wey; Nicholas Salkowski; Walter K Kremers; Cory R Schaffhausen; Bertram L Kasiske; Ajay K Israni; Jon J Snyder
Journal:  Am J Transplant       Date:  2017-10-17       Impact factor: 8.086

4.  In vitro and In vivo assessment of a novel organ perfusion stent for successful flow separation in donation after cardiac death.

Authors:  Moataz Elsisy; Bryan Tillman; Lynn Chau; Catherine Go; Sung Kwon Cho; Youngjae Chun
Journal:  J Biomater Appl       Date:  2022-04-25       Impact factor: 2.712

5.  Donation after brain death followed by circulatory death, a novel donation pattern, confers comparable renal allograft outcomes with donation after brain death.

Authors:  Qipeng Sun; Honglan Zhou; Ronghua Cao; Minzhuan Lin; Xuefeng Hua; Liangqing Hong; Zhengyu Huang; Ning Na; Ruiming Cai; Gang Wang; Fanhang Meng; Qiquan Sun
Journal:  BMC Nephrol       Date:  2018-07-04       Impact factor: 2.388

6.  Surgical and logistical concerns for ex vivo-based perfusion strategies for "donation after circulatory death" multiorgan recovery.

Authors:  Masaki Funamoto; Richard N Pierson; Justin H Nguyen; David A D'Alessandro
Journal:  JTCVS Tech       Date:  2021-11-12

7.  Supplemental hydrogen sulfide in models of renal transplantation after cardiac death.

Authors:  Smriti Juriasingani; Vicky Vo; Masoud Akbari; Jaskiran Grewal; Max Zhang; Jifu Jiang; Aaron Haig; Alp Sener
Journal:  Can J Surg       Date:  2022-03-15       Impact factor: 2.089

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.